CVAC is no longer listed. Its last trade on record was Jan 6, 2026. The price and figures on this page are from its last trading day and final filings, and are no longer updated.
CureVac's reliance on lumpy, non-recurring milestone payments creates significant revenue volatility, as evidenced by a 91.4% year-over-year revenue decline in 2025Q2.
Price trend, volume and key moving averages
Trailing total returns as of 11/9/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2025Latest Nov 24, 2025 | -$0.10+41.2% vs -$0.17 | $573M vs — |
Q3 2025 Aug 15, 2025 | -$0.30-66.7% vs -$0.18 | $1M-62.7% vs $4M |
Q2 2025 May 20, 2025 | -$0.24-50.0% vs -$0.16 | $978,951-79.7% vs $5M |
Q2 2025 Apr 10, 2025 | -$0.15+31.8% vs -$0.22 | $15M+122.7% vs $7M |
Benchmark CVAC against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for CureVac N.V. (CVAC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.66 | $1.05B | 5.75 | 895.54% | 30.3% | 26.73% | — | |
| $254.19 | $100.86B | -35.01 | -39.23% | -141.43% | -39.2% | — | |
| $87.51 | $21.98B | -17.36 | 0.2% | -61.28% | -8.06% | — | |
| $10.35 | $294.18M | -4.31 | -51.43% | -391.9% | -46.54% | — | |
| $11.35 | $1.27B | -2.98 | 16.92% | -672.16% | -57.79% | — | |
| $26.41 | $2.72B | -32.60 | 120.01% | -73.04% | -9.69% | — |
CureVac N.V. (CVAC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when CVAC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CureVac N.V. (CVAC) stock FAQ — growth, dividends, profitability & financials explained
CureVac N.V. (CVAC) reported $510.5M in revenue over the trailing twelve months. Revenue was $535.2M in fiscal year 2024. That is 4058% more than the $12.9M of fiscal year 2018.
CureVac N.V. (CVAC) grew revenue by 895.5% in fiscal year 2024, compared with the prior fiscal year.
Yes. CureVac N.V. (CVAC) earned $193.6M in net income over the trailing twelve months (a 37.9% net margin).
CureVac N.V. (CVAC) had a return on equity (ROE) of 26.7% in fiscal year 2024. That is well above the market's typical 10-15%.
CureVac N.V. (CVAC) generated $196.1M in free cash flow over the trailing twelve months.
